Head-to-head evidence
fluticasone furoate/vilanterol vs fluticasone propionate/salmeterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/vilanterol
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
fluticasone propionate/salmeterol
Developed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The trial randomized 908 participants to combination therapy, fluticasone propionate, or placebo under double-blind conditions. Its primary endpoint was change in daily evening peak expiratory flow after 12 weeks, a pulmonary-function surrogate, and the registry does not report whether this endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · fluticasone propionate/salmeterol's landscape